Axcella to Report Third Quarter 2020 Financial Results and Hold Conference Call on November 12, 2020
October 29 2020 - 8:00AM
Business Wire
Conference call to take place at 8:30 a.m.
ET
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company
pioneering a new approach to treat complex diseases and improve
health using endogenous metabolic modulator (EMM) compositions,
today announced that it plans to report its third quarter financial
results and other business updates on November 12, 2020. The
company will host a conference call at 8:30 a.m. ET that
morning.
The conference call webcast will be available in the Investors
& News section on the company’s website at
www.axcellahealth.com. To access the call via telephone, please
dial (866) 652-5200 (U.S. toll free) or (412) 317-6060
(international) five minutes prior to the start time. For those
unable to listen in live, a webcast archive will be available on
the company’s website for 30 days following the call.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of
disclosing material nonpublic information and for complying with
its disclosure obligations under Regulation FD. Such disclosures
will be included on the company’s website in the “Investors and
News” section. Accordingly, investors should monitor this portion
of the company’s website, in addition to following its press
releases, SEC filings and public conference calls and webcasts.
About Axcella
Axcella is a clinical-stage biotechnology company pioneering a
new approach to treat complex diseases and improve health using
endogenous metabolic modulator (EMM) compositions. The company’s
product candidates are comprised of EMMs and their derivatives that
are engineered in distinct combinations and ratios to
simultaneously impact multiple biological pathways. Axcella’s
pipeline includes lead therapeutic candidates for non-alcoholic
steatohepatitis (NASH) and the reduction in risk of overt hepatic
encephalopathy (OHE) recurrence. Additional muscle- and
blood-related programs are in earlier-stage development. For more
information, please visit www.axcellahealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201029005011/en/
Company Contact Jason Fredette
jfredette@axcellahealth.com 857.320.2236
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Sep 2023 to Sep 2024